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PENJANAAN ANTIBODI BERFUNGSI SEPERTI RESEPTOR SEL T 
REAKTIF TERHADAP 16 kDa PROTEIN KEJUTAN HABA (HSP) 





 Antibodi berfungsi seperti reseptor sel T juga dikenali sebagai antibodi 
mimik reseptor sel T telah menarik perhatian ramai penyelidik sejak kebelakangan ini 
kerana fungsinya yang menggabungkan ciri keistimewaan keimunan humoral and 
keimunan perantaraan sel dalam satu platform. Ini dimungkinkan oleh perkembagaan 
teknologi, khususnya kejuruteraan genetik dan pameran faj. Focus utama kajian ini 
bertumpu kepada penjanaan antibodi mimik reseptor sel T, yang boleh menyumbang 
kepada pembangunan diagnostik dan terapeutik tuberkulosis pendam kerana beban 
global tuberkulosispendam terus meningkat. Sebagai sasaran, peptida protein HSP 16 
kDa antigen Mycobacterium tuberculosis (Mtb) yang dipaparkan oleh kompleks 
histocompatible utama (MHC) HLA-A*2, HLA-A*11 dan HLA-A*24 telah 
digunakan dalam kajian ini. Protein HSP 16 kDa merupakan calon yang sesuai bagi 
penyelidikan tuberkulosis pendam kerana ia berfungsi untuk memastikan bakteria 
tuberkulosis hidup dalam tempoh dorman. Kesemua kompleks peptida antigen 16 kDa 
MHC telah dihasilkan melalui proses pertukaran peptida berintegrasi sinaran UV. 
Sebelum itu, kompleks peptida UV-sensitif MHC bagi setiap HLA telah dihasilkan 
melalui penggabungan rantai berat HLA yang specifik, rantai ringan β2M bersama 
dengan peptida sensitif-UV. Pendedahan terhadap sinaran UV menyebabkan peptida 




untuk membentuk kompleks peptida sasaran 16 kDa MHC. Teknik panning plat 
konvensional telah diaplikasikan bagi pemilihan antibodi mimik reseptor sel T dengan 
menggunakan perpustakaan faj antibodi domain manusia. Perpustakaan antibodi 
domain manusia yang digunakan dibina berdasarkan segmen rantai berat VH3-23 
dengan kepelbagaian sintetik yang diperkenalkan ke wilayah CDR1, CDR2 dan 
CDR3. Berdasarkan kepada analisis jujukan, setiap sasaran HLA memperolehi sebuah 
monoklon antibodi mimik reseptor sel T (HLA-A * 2: A2 / Ab; HLA-A * 11: A11 / 
Ab; HLA-A * 24: A24 / Ab). Selain itu, analisis jujukan juga telah  mendedahkan 
bahawa klon A2 / Ab tergolong dalam IGHV3 V-gen, IGHD3-9 * 01 D-segmen, 
IGHJ4 * 01 J -segmen; klon A11 / Ab tergolong dalam IGHV3 V-gen, IGHD3-16 * 
01 D-segmen, IGHJ4 * 02 J-segmen; dan klon A24 / Ab tergolong dalam IGHV3 V-
gen, IGHD2-8 * 02 D-segmen, IGHJ4 * 02 J-segmen. Penghasilan protein monoklon 
antibodi mimik reseptor sel T A2/Ab, A11/Ab dan A24/Ab berjaya tercapai. Dari segi 
fungsi, ketiga-tiga protein antibodi bekebolehan untuk berfungsi dalam keadaan larut, 
di samping dengan memaparkan  interaksi yang kuat dengan sasaran antigen 16 kDa 
masing-masing. Sebagai kesimpulan, penemuan daripada kajian ini dapat 
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Mycobacterium tuberculosis 16 kDa HEAT SHOCK PROTEIN FROM A 





T cell receptor (TCR)-like antibody has drawn the attention of many 
researchers recently due to its dual functionality of sandwiching the best of the 
humoral (antibody) and cell-mediated immunity (T cell) in a single platform. This is 
possible through the advancement in technology, specifically genetic engineering and 
phage display. The primary focus of this study was to generate TCR-like antibody for 
the development of latent tuberculosis diagnostics and therapeutics since the global 
burden contributed by latent tuberculosis is constantly increasing. As targets, 
Mycobacterium Tuberculosis (Mtb) heat shock protein (HSP) 16kDa antigen peptide 
presented by the major histocompatible complex (MHC) HLA-A*2, HLA-A*11 and 
HLA-A*24 were used in this study. The 16 kDa antigen heat shock protein is 
responsible for the survival of the TB bacilli during dormancy, making the protein a 
suitable candidate for latent tuberculosis investigation. Target peptide-MHC 
complexes were generated via a UV-mediated peptide exchange process. Prior to 
peptide exchange, UV-sensitive photolabile peptide-MHC complex of all three HLAs 
were formed by refolding each of the HLA heavy and β2M light chains along with a 
UV-sensitive peptide. Upon UV exposure, the photolabile peptide was cleaved at the 
UV-sensitive amino acid site allowing the exchange of 16 kDa antigen target peptide 




technique was applied for the selection of TCR-like antibody using a human domain 
antibody phage library. The human domain antibody library used was constructed 
based on the VH3-23 heavy chain germ-line segment with synthetic diversity 
introduced into CDR1, CDR2 and CDR3 regions. For each HLA target, a single TCR-
like domain antibody clone (HLA-A*2: A2/Ab; HLA-A*11: A11/Ab; HLA-A*24: 
A24/Ab) was successfully obtained and confirmed via sequence analysis. The 
sequence analysis revealed that clone A2/Ab belongs to IGHV3 V-gene, IGHD3-9*01 
D-segment, IGHJ4*01 J-segment; clone A11/Ab belongs to IGHV3 V-gene, IGHD3-
16*01 D-segment, IGHJ4*02 J-segment; and clone A24/Ab belongs to IGHV3 V-
gene, IGHD2-8*02 D-segment, IGHJ4*02 J-segment. In addition to the successful 
expression and purification of all three clones, the generated A2/Ab, A11/Ab, and 
A24/Ab TCR-like antibody proteins proved to be functional in soluble form and 
exhibited strong binding capacity against their respective 16 kDa antigenic targets. In 
conclusion, the favourable findings of this study serve as a propitious platform for the 






1.1 Overview of the immune system 
The immune system is a diverse defence system that has evolved in order to protect 
individuals from invading pathogenic microorganism and cancer (Judith et al., 2013). 
The system is capable of generating a huge diversity of cells and molecules that are 
able to recognize as well as eliminate a diversity of foreign invaders. It is able to 
differentiate healthy, unhealthy and infected cells from each other by identifying fine 
chemical alternations and danger signals called danger associated molecular pattern 
(DAMPs). It also has the capacity to distinguish between foreign bodies (non-self) 
and the body’s own cells and proteins (self) by recognizing a set of signals emitted by 
the infectious microbe known as pathogen-associated molecular patterns (PAMPs)  
(Shefali Khanna Sharma & Naidu, 2016).  
In general, the human immune system is divided into innate and adaptive 
immune system that work hand in hand to counteract a threat as illustrated in Figure 
1.1. Once a foreign body has been distinguished, the innate immune (non-specific) 
system acts as a first line of defence. The innate immune system (Figure 1.1 (a)) 
comprises of cells and proteins that are constantly present and prepared to counteract 
or eliminate threats. Components of the innate immune system include physical 
epithelial barriers, phagocytic leukocytes, dendritic cells, natural killer (NK) cells and 
circulating plasma proteins such as lysozyme, interferon, and complement (Wood, 
2006c). These soluble proteins contribute significantly to the immune system upon 




The adaptive immune system (Figure 1.1 (b)) comes in control in the event 
pathogens are able to evade and overcome the innate immune defences or if the 
pathogens persist. Adaptive immune responses are antigen-specific whereby it is 
capable of recognizing and eliminating specific foreign microorganisms in contrast to 
the general response of the innate immune system to a microorganism species or 
cancerous cells (Chaplin, 2010). In other words, the adaptive immune system 
responds differently to all members of a pathogen species. The adaptive immune 
system displays significant characteristics, which includes antigenic specificity, 
diversity in recognition, immunological memory, and recognition of self and non-self 
(Judith et al., 2013). The major components of adaptive immune response are 
lymphocytes and antigen-presenting cells. The two key players, B (humoral immunity) 
and T (cell-mediated immunity) lymphocytes/cells are significantly different in terms 







Figure 1.1 Overview of the immune system whereby the innate and adaptive immune system works hand in hand to provide defence. (a) 
Components of the innate immune system act as the first line of defence upon exposure to antigen. The antigen presenting cells such as dendritic 
cells and macrophages present antigenic peptides for further processing by the adaptive immune components (lymphocytes). (b) The adaptive 







1.2 B-cell mediated immunity 
Antibodies, known as immunoglobulins (Ig) are glycoproteins secreted by the plasma 
B cells with its primary role in humoral immune responses. It was initially identified 
to be residing in the serum by A. Tiselius and E. A.Kabat, in 1939 (Buchacher & 
Iberer, 2006). In general, antibodies exist as soluble and/or membrane-bound in the 
immune system (Wood, 2006c). The membrane-bound antibody generated by a 
naive/immature B cell acts as a B cell receptor (BCR) for antigen recognition(Alberts 
et al., 2002a). Upon antigen activation (with the aid of helper T cell), the naive B cell 
undergoes clonal expansion in which cell proliferation and differentiation occurs to 
form antibody-secreting plasma cells and memory B cell as shown in Figure 1.2 (J. A. 
Owen et al., 2013a). Simultaneously, the affinity maturation process of generating 
antibodies with higher binding affinities towards the encountered antigen takes place 







Figure 1.2 Activation of B cell upon antigen recognition. The activated B cell 
undergoes clonal expansion to generate memory B cells and plasma cells which 




1.3 Antibody and its structure  
The basic antibody molecule structure is characterized as a Y-shaped structure that 
consists of two identical heavy (H) (~50 kDa) and light (L) (~25 kDa) peptide chains 
with disulfide bonds holding each heavy chain to a light chain and at the same time 
clutches the two pairs together (Wood, 2006c). There are two types of light chain 
termed as kappa(κ) and lambda (λ) (Esparvarinha et al., 2017). They share similar 
structures but vary in the genes coded and exist independently from each other in an 
antibody molecule. The lambda (λ) genes are encoded on chromosome 22 while the 
kappa (κ) genes are encoded on chromosome 2 (Townsend et al., 2016). It has been 
reported that the distribution of kappa (60%) light chain antibody in human peripheral 
blood is higher compared to the lambda (40%) light chains (J. Owen et al., 2007). On 
the other hand, there are five distinct heavy chains (α, μ, δ, γ and ε) located at the 
constant region of an antibody which contributes to the antibody isotyping and its 
respective functions (Alberts et al., 2002a).  The antibody structure is further divided 
into a variable (V) and constant (C) region that covers the top and stem of the Y 
structure respectively (Wang et al., 2007). The variable region of the light (VL) and 
heavy (VH) chain is made up of approximately 110 amino acid each and is responsible 
for antigen binding as well as the distinct specificity displayed by the different 
antibodies while the constant region of the light (CL) and heavy (CH) comprises of a 
rather constant sequence and remains the same between antibodies (Janeway et al., 
2001b).  
 The dissection of the antibody molecule structure via protease papain cleaves 
the structure into three fragments. The first two identical fragments known as 
fragment antigen binding (Fab) fragments consist of the entire light chains coupled 




associated with antigen binding function (Schroeder & Cavacini, 2010). The third 
fragment termed as fragment crystallizable (Fc) fragments which consist of two 
identical fragments derived from constant heavy chain 2 (CH2) and constant heavy 
chain 3 (CH3) domains (IgM and IgG consist of second, third and fourth CH domains), 
not only are responsible for the isotyping and subclassification of antibodies but also 






Figure 1.3 Basic structure of an antibody molecule. The antibody comprises two 
heavy and light chains. Disulfide bonds link the heavy to the light chains and also 






1.4 Antibody isotypes 
In general, the antibody mediates several effector functions as part of its role in 
providing immune defence. Some of the antibody-mediated effector roles include 
opsonization, activation of the complement system, antibody-dependent cell-mediated 
cytotoxicity (ADCC) and transcytosis (J. Owen et al., 2007). The various features of 
the Fc fragment are responsible for these effector mechanisms resulting in the 
existence of the diverse antibody isotypes which are classified based on the distinct 
heavy chains acquired (Spiegelberg, 1974). The five isotypes of antibody in human 
are IgA (α), IgM (μ), Ig D (δ), IgG (γ) and Ig E (ε) as shown in Figure 1.4 (K. Chen 
& Cerutti, 2011).  
 IgG, the most prevailing antibody among all immunoglobulins comprises of 
two heavy and light chains and is subdivided into four classes (Ig G1, Ig G2, Ig G3, 
and Ig G4) each singularized based on the gamma (γ) chain sequence variation 
(Vidarsson et al., 2014). The functionalities of the IgG subclasses are determined by 
the individual amino acid acquired by each class. One of the prominent roles of IgG in 
immune defence specifically Ig G1, Ig G2 and Ig G3 (most effective) are as the 
activators of the complement cascade pathway (Giuntini et al., 2012). Another 
effector function of IgG is transplacental transport in which Ig G1, Ig G3, and Ig G4 
are capable of crossing through placenta ensuring protection for the growing fetus 
(Palmeira et al., 2012). The IgG subclasses also act as opsonization mediators with Ig 
G1 and Ig G3 possessing the strongest affinity to Fc receptors compared to Ig G2 and 
Ig G4 (J. Owen et al., 2007).  
 Ig M is the preliminary antibodies produced upon initial exposure to an 




disulfide bonds and polypeptide joining (J) chains giving a total of ten antigen-
binding sites (Schroeder & Cavacini, 2010). The pentameric structure of Ig M 
contributes eminently to its roles as well as the high capability of antigen binding 
when compared to other Ig molecules. The prominent functions of Ig M include 
activating the complement pathway, neutralizing bacterial and viral infection, 
complementing IgG responses and also act as a secretory antibody (Boes, 2000).  
 Ig D was initially discovered when a tested myeloma protein failed to respond 
to the then available antisera of Ig A, Ig M, and IgG which resulted in the further 
analysis that substantiated its existence (Black, 1997). Ig D is found to be expressed 
along with Ig M by the mature B cells (Rogers et al., 2006). Structurally, Ig D 
possesses a standard Ig molecular complex and is detected at a minimal level in serum 
concentration (Janeway et al., 2001b). The functions of Ig D were poorly understood 
initially although later studies highlighted Ig D’s immune functions that included 
enhancement of the mucosal immunity, activation of several innate cells such as 
basophils and mast cells and stimulation of proinflammatory roles (K. Chen & Cerutti, 
2011).   
 Ig A is the most predominant secretory immunoglobulin found in secretions 
like maternal milk, tears, saliva, and mucus (Woof & Kerr, 2006). Basically, Ig A 
exists as monomers although it may form polymers with all forms acquiring a J-chain 
polypeptide (Suzuki et al., 2015). The two subdivision of Ig A, IgA1 and IgA2 are 
differentiated based on the length of the respective hinge regions (Wood, 2006c). In 
terms of function, Ig A provides protection against virus and bacteria by prohibiting 
pathogen attachment to the mucosal cells. Another prominent function of Ig A is to 
deliver neonatal immunity (passive immunity) through breast milk which highlights 




The existence of Ig E was first evidenced by Prausnitz and Kustner who later 
authenticated Ig E’s role in type 1 hypersensitivity reactions (Hamilton, 2005). 
Having structural similarity to a basic Ig structure, Ig E is present at a very low level 
in human sera. Ig E is found to be responsible for arbitrating the instantaneous 
hypersensitivity reactions precisely by activating mast and basophil cells and antigen 
presentations in addition to its counter to parasitic worm infection (C. E. Owen, 2007) 

















1.5 Mechanism of action of antibody  
An antibody plays multiple roles in mediating immune responses including 
neutralization, agglutination, opsonisation, activation of complement and antibody-
dependent cell-mediated cytotoxicity. The mechanism of pathogen neutralization 
varies according to the pathogen. The antibody neutralizes toxin by binding to the 
toxin and hampering its effects, neutralizes virus by binding to the viral receptor to 
prevent viral attachment to the host cell and lastly inhibiting the metabolism of 
bacteria by interfering the adherence of bacteria to the host cells (Forthal, 2014). In 
terms of agglutination, the antibody confines the pathogens in clumps which prevent 
the escape of pathogens from the infection sites for elimination by phagocytosis 
(Roche et al., 2015). Another prominent function of the antibody is opsonisation 
whereby the dual binding of the antibody molecule to the pathogen through its Fab 
region and the phagocyte receptors via Fc portion respectively, induces the 
phagocytosis of the pathogen (Hart et al., 2004). Activation of the complement system 
is another important role of an antibody (IgM and some of the IgG subclasses only) 
which leads to the complement-dependent cell cytotoxicity (Charles A Janeway & 
2001). The complement system consists of a cascade of interconnected proteins which 
upon activation, contribute to the immune defence through inflammation, chemotaxis 
of eosinophils, neutrophils and monocytes, and activation of mast cell and neutrophils 
(Wood, 2006a). The final and essential role of antibody is to mediate antibody-
dependent cell-mediated cytotoxicity (ADCC). This is possible due to once again the 
dual binding features of the antibody of binding to the infected target cells (Fab region) 
and cells such as neutrophils, macrophages and natural killer cells (Fc part), resulting 












1.6 Cell-mediated immunity  
Cell-mediated immunity plays a fundamental role in the immune defence and the T 
lymphocyte/cell is the ace behind it. The generation of T cells begins in the bone 
marrow similar to B cells followed by maturation in the thymus prior to the 
circulation of the mature T cells in the blood and lymphoid tissues(Ochoa & 
Makarenkova, 2005). The helper and cytotoxic T cells are distinguished based on 
distinctive cell surface molecules expressed separately on the two subsets of T cells 
that are directly involved in cell-mediated immune responses (LaRosa & Orange, 
2008).  
 Antigen recognition by both helper and cytotoxic T cells are possible through 
the actions of T cell receptor (TCR) which distinguishes foreign/antigenic peptides 
displayed on cell surface glycoproteins known as major histocompatible complex 
(MHC) molecules (Janeway et al., 2001a). Structurally, TCR is a heterodimer that 
comprises of an α and β glycoprotein chain linked via disulfide bond with each chain 
acquiring a constant and variable domain (Figure 1.6) (Wood, 2006d). The capability 
of TCR in recognizing a wide range of antigenic peptide-MHC is contributed largely 
by the variable domain which is generated from diversification of the variable (V), 
diversity (D) and joining (J) gene segments (Huang et al., 2012). The TCR is also 
associated with a group of signalling proteins known as CD3 proteins, subdivided into 
gamma (γ), delta (δ), epsilon (ε), zeta (δ) and eta (ε) that are responsible for activating 
the intracellular signaling pathway upon antigen recognition by TCR (Choudhuri et al., 





Figure 1.6 Typical structure of the T cell receptor (TCR). The T cell receptor is 
made up of an alpha and beta glycoprotein chains coupled with a group of CD3 








1.7 Mechanism of action of T cells 
The three subpopulations of T cells, cytotoxic T cells (CD8 T cells), helper T cells 
(CD4 T cells) and regulatory T cell (Treg) play exclusive roles as part of the immune 
defence. As the name implies, cytotoxic T cells are responsible in eliminating infected 
cells upon recognizing the antigenic peptide presented by the MHC class I of the cells 
(M. H. Andersen et al., 2006). The two different elimination mechanisms exhibited by 
the cytotoxic T cells are granule exocytosis which involves proteins such as perforin 
and granzymes found in the granules of the cytotoxic T cell as well as the Fas 
pathway (Henkart & Sitkovsky, 1994). The helper T cells recognize antigenic 
peptides presented on the MHC class II molecule of antigen presenting cells and 
differentiates into two subclasses (TH1 and TH2 ) that determine its function (Wood, 
2006b). The TH1 cells secrete cytokines such as interferon-gamma (IFN- γ) and 
tumour necrosis factor-alpha (TNF-α), which activates the macrophages to eliminate 
phagocytosed pathogens, activates cytotoxic T cells and stimulate B cells for antibody 
secretion targeting intracellular microbes(Wan, 2010). On the other hand, the TH2 
cells secrete interleukins and are associated with defense against the extracellular 
pathogen, mucosal immunity in the lungs and B cell stimulation for antibody 
secretion(Alberts et al., 2002b). Contrary to cytotoxic and helper T cells, the 
regulatory T cells are associated with immune suppression in order to maintain the 










1.8 Major histocompatible complex (MHC) and antigen recognition   
Antigen recognition by T cells differs from an antibody in a way that T cells 
specifically distinguish antigenic peptides presented by the MHC molecules and do 
not recognize free antigens. As such, the essential role of MHC molecules in cell-
mediated immunity is undeniable. In general, MHC molecules are also known as 
human leukocyte antigen (HLA). In human, MHC molecules are highly diversified 
glycoproteins encoded by the MHC genes (Alberts et al., 2002c). Class I and class II 
are the two main classes of MHC molecules involved in T cell’s antigen recognition 
(Wieczorek et al., 2017). In terms of its structure, the MHC class I molecule consists 
of a lengthier heavy alpha (α) chain (45 kDa) linked to the β2-microglobulin light 
chain (12 kDa) and are expressed on the surface of all nucleated cells while the MHC 
class II molecule which comprises of an alpha chain (30-35 kDa) and beta chain (26-
30 kDa) is predominantly expressed on antigen presenting cells such as dendritic cells, 
macrophages, and B cells (Williams et al., 2002)  (Wood, 2006d). In human, there are 
three loci for each MHC class termed as HLA-A-A, HLA-A-B, HLA-A-C for MHC 
class I and HLA-DP, HLA-DQ, HLA-DR for MHC class II (Wieczorek et al., 2017).  
The T cell subsets are associated with different MHC molecules (Figure 1.8). 
The MHC class I molecule contributes largely in maintaining internal 
immunosurveillance by displaying antigenic peptides derived from infected or 
mutated cells to cytotoxic T cells resulting in the elimination of the infected cells 
(Rock et al., 2016). On the other hand, MHC class II molecules present foreign 
peptides to helper T cell which transmits intracellular signals that help as its name 
suggest, to initiate B cells for antibody production and secretion, macrophages for 






Figure 1.8 Antigenic peptide presentation by MHC class I and II to the respective 





1.9 Antibody phage display technology  
The need for antibodies is constantly increasing as antibodies play a crucial role in the 
diagnostic and immunotherapy of numerous diseases. Traditionally, antibodies were 
generated by vaccinating animal model such as mouse, with the target antigen 
followed by extraction of antibodies from the blood serum. However,  the generated 
antibodies were generally of poor quality and quantity (Dimitrov, 2010). This led to 
the discovery of other alternative methods including hybridoma and phage display 
technology.  
 The pioneer breakthrough of the production of monoclonal antibodies via 
hybridoma technology in 1975 opened the door for the application of antibody-based 
therapy in many diseases including infectious diseases and cancer (Freysd'ottir, 2000). 
To this date, there are approximately forty-seven monoclonal antibody products 
approved by the Food and Drug Administration (FDA), USA for the treatment of 
various diseases (Ecker et al., 2015). The hybridoma technology begins with the 
immunization of a specific organism with the antigen, harvesting the B lymphocytes 
upon expected immune response before fusing the cells with an immortal myeloma 
cell line in order to generate the hybridoma  (antibody producing) cells and finally the 
cells undergo a final selection process to obtain the desired monoclonal antibody 
(Hanack et al., 2016). Although the technology provided a fundamental platform for 
monoclonal antibody generation, the method also drew several setbacks including 
being laborious, generated antibodies that were influenced by the immune system of 
the animal model and immunogenicity through human anti-mouse antibodies (HAMA) 




The evolution of generating monoclonal antibody from hybridoma to phage 
display technology occurred in 1985 through the discovery of Dr George Smith 
(Bazan et al., 2012).  Based on the understanding that phage genotype and phenotype 
are physically linked, phage display technology involves the cloning of the 
desired/target gene into a vector fused with the PIII coat protein gene of a filamentous 
bacteriophage. Utilizing E.coli cells as host, propagation occurs with the generated 
phagemid displaying the target genes and further in vitro manipulation enables the 
production of the desired soluble proteins applicable for diagnostics and therapeutics 
(Dantas-Barbosa et al., 2012) (Liu, 2014).  
Antibody phage display technology is the in vitro selection of monoclonal 
antibody using a high diversity antibody phage display library which consists of 
bacteriophages displaying antibody fragments of a certain format followed by several 
rounds of antigen-based selection (Hammers & Stanley, 2014). In comparison to 
hybridoma technology, antibody phage display technology serves several plus points 
which include rapid and large-scale antibody generation, flexible to automated 
selection and screening, enhanced tissue penetration due to small antibody fragment 
format and reduced immunogenicity as immunization is not required (Bradbury et al., 
2011). As such, there is a drastic increase in the number of phage display-derived 
antibodies in clinical trials after the successful generation of the first Food and Drug 
Administration (FDA) approved phage display antibody, Adalimumab (Dantas-







1.9.1 M13 bacteriophage  
The M13 filamentous bacteriophage is one of the most commonly used phage in 
antibody phage display system with a basic viral structure of single-stranded viral 
DNA and protein capsid and known to infect gram-negative bacteria such as 
Escherichia coli (E. coli) (Figure 1.9)  (Bazan et al., 2012). The phage is 
approximately 900 to 2000 nm in length and 7 nm wide, enveloping the entire DNA 
genome of 11 genes in a long cylinder (Khalil et al., 2007). A breakdown of the 
eleven M13 genes function revealed that gene I, IV and XI are for phage assembly, 
gene II and X for DNA replication, gene III, VI, VII and IX for minor capsid protein, 
gene VII for major capsid protein and finally gene V for single-stranded (ss) DNA 
binding (Webster, 1996).  
 The life cycle of M13 phage begins with the fusion of phage to the bacterium 
via interaction between the N2 domain of the pIII minor protein capsid and the F pilus 
tip of the bacterium which mediates the binding of pIII-N1 domain to surface co-
receptor TolA protein of the E.coli resulting in the depolymerisation of the protein 
coat and subsequent transfer of the phage single-stranded DNA (ssDNA) into the host 
(Click & Webster, 1997). The ssDNA is supplemented with a complementary DNA 
strand by the host to form double-stranded DNA phage chromosome termed as 
replicative form (RF) (Rakonjac et al., 2017). Phage assembly takes place at the 
bacterial envelope and the newly assembled phage is secreted into the media 
(Ledsgaard et al., 2018). The overview of the M13 phage life cycle is shown in 
Figure 1.10.  
  M13 bacteriophage-based phage display system delivers several benefits to the 




easily manageable throughout the biopanning process as the M13 is non-lytic in 
addition to the high stability, tolerance to high temperature and extreme conditions 
acquired by the phage which further proves the capability and suitability of M13 
phage (Shim, 2017).  
  
